Pre-NDA to CDE of NMPA submitted in China for asandeutertinib (TY-9591)

This Pre-NDA submission is based on the outstanding results of the TYKM1601202 study (ESAONA), a prospective, multicenter, randomized, active-controlled, pivotal registrational study. The study aimed to evaluate the efficacy and safety of asandeutertinib compared to osimertinib in first-line treatment of NSCLC patients with brain metastases. Led by Professor Yuankai Shi of the Cancer Hospital of the Chinese Academy of Medical Sciences, the study involved a total of 53 centers, including Shandong Cancer Hospital and Hunan Cancer Hospital. For more details on the study, please refer to clinicaltrials.gov, NCT05948813.

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib